Search Results - "DIAMANT, Michaela"

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes by Inzucchi, Silvio E, Bergenstal, Richard M, Buse, John B, Diamant, Michaela, Ferrannini, Ele, Nauck, Michael, Peters, Anne L, Tsapas, Apostolos, Wender, Richard, Matthews, David R

“…In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management…”
Get full text

GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans by van Bloemendaal, Liselotte, IJzerman, Richard G, Ten Kulve, Jennifer S, Barkhof, Frederik, Konrad, Robert J, Drent, Madeleine L, Veltman, Dick J, Diamant, Michaela

“…Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the…”
Get full text

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial by Diamant, Michaela, Prof, Van Gaal, Luc, Prof, Stranks, Stephen, MD, Northrup, Justin, MPT, Cao, Dachuang, PhD, Taylor, Kristin, PhD, Trautmann, Michael, MD

“…Summary Background Diabetes treatments are needed that are convenient, provide effective glycaemic control, and do not cause weight gain. We aimed to test the…”
Get full text

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial by van Beers, Cornelis A J, Dr, DeVries, J Hans, Prof, Kleijer, Susanne J, MD, Smits, Mark M, MD, Geelhoed-Duijvestijn, Petronella H, MD, Kramer, Mark H H, Prof, Diamant, Michaela, Prof, Snoek, Frank J, Prof, Serné, Erik H, MD

“…Summary Background Patients with type 1 diabetes who have impaired awareness of hypoglycaemia have a three to six times increased risk of severe hypoglycaemia…”
Get full text

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? by Muskiet, Marcel H. A., Smits, Mark M., Morsink, Linde M., Diamant, Michaela

“…Key Points Incretin-based therapies—glucagon-like peptide 1 receptor (GLP-1R) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors—improve glycaemic control…”
Get full text

Myocardial Steatosis Is an Independent Predictor of Diastolic Dysfunction in Type 2 Diabetes Mellitus by Rijzewijk, Luuk J., MD, van der Meer, Rutger W., MD, Smit, Johannes W.A., MD, PhD, Diamant, Michaela, MD, PhD, Bax, Jeroen J., MD, PhD, Hammer, Sebastiaan, MSc, Romijn, Johannes A., MD, PhD, de Roos, Albert, MD, PhD, Lamb, Hildo J., MD, PhD

“…Objectives The purpose of this study was to compare myocardial triglyceride content and function between patients with uncomplicated type 2 diabetes mellitus…”
Get full text

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial by Diamant, Michaela, Prof, Van Gaal, Luc, Prof, Guerci, Bruno, Prof, Stranks, Stephen, MD, Han, Jenny, MS, Malloy, Jaret, PhD, Boardman, Marilyn K, PharmD, Trautmann, Michael E, Dr

“…Summary Background When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1)…”
Get full text

Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study by Schindhelm, Roger K, Dekker, Jacqueline M, Nijpels, Giel, Bouter, Lex M, Stehouwer, Coen D.A, Heine, Robert J, Diamant, Michaela

“…Abstract Alanine aminotransferase (ALT) is a marker of non-alcoholic fatty liver disease (NAFLD) and predicts incident type 2 diabetes mellitus (DM2)…”
Get full text

Pancreatic Fat Content and β-Cell Function in Men With and Without Type 2 Diabetes by Tushuizen, Maarten E, Bunck, Mathijs C, Pouwels, Petra J, Bontemps, Saskia, van Waesberghe, Jan Hein T, Schindhelm, Roger K, Mari, Andrea, Heine, Robert J, Diamant, Michaela

“…OBJECTIVE:--Insulin resistance, associated with increased lipolysis, results in a high exposure of nonadipose tissue to lipids. Experimental data indicate that…”
Get full text

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition by Bunck, Mathijs C, Diamant, Michaela, Eliasson, Bjorn, Cornér, Anja, Shaginian, Rimma M, Heine, Robert J, Taskinen, Marja-Riitta, Yki-Järvinen, Hannele, Smith, Ulf

“…To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. Metformin-treated patients with type 2 diabetes (N = 69)…”
Get full text

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing by Fineman, Mark, Flanagan, Shawn, Taylor, Kristin, Aisporna, Maria, Shen, Larry Z., Mace, Kenneth F., Walsh, Brandon, Diamant, Michaela, Cirincione, Brenda, Kothare, Prajakti, Li, Wen-I, MacConell, Leigh

“…Background and Objectives Exenatide is a glucagon-like peptide-1 receptor agonist, available in an immediate-release (IR), twice-daily formulation, which…”
Get full text

Alterations in white matter volume and integrity in obesity and type 2 diabetes by van Bloemendaal, Liselotte, Ijzerman, Richard G., ten Kulve, Jennifer S., Barkhof, Frederik, Diamant, Michaela, Veltman, Dick J., van Duinkerken, Eelco

“…Type 2 diabetes mellitus (T2DM) is characterized by obesity, hyperglycemia and insulin resistance. Both T2DM and obesity are associated with cerebral…”
Get full text

Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes by Rijzewijk, Luuk J., MD, Jonker, Jacqueline T., MD, van der Meer, Rutger W., MD, PhD, Lubberink, Mark, PhD, de Jong, Hugo W., PhD, Romijn, Johannes A., MD, PhD, Bax, Jeroen J., MD, PhD, de Roos, Albert, MD, PhD, Heine, Robert J., MD, PhD, Twisk, Jos W., MD, PhD, Windhorst, Albert D., PhD, Lammertsma, Adriaan A., PhD, Smit, Johannes W.A., MD, PhD, Diamant, Michaela, MD, PhD, Lamb, Hildo J., MD, PhD

“…Objectives The purpose of this study was to investigate the relationship between hepatic triglyceride content and both myocardial function and metabolism in…”
Get full text

Associations between life stress and subclinical cardiovascular disease are partly mediated by depressive and anxiety symptoms by Bomhof-Roordink, Hanna, Seldenrijk, Adrie, van Hout, Hein P.J, van Marwijk, Harm W.J, Diamant, Michaela, Penninx, Brenda W.J.H

“…Abstract Background Stress experienced during childhood or adulthood has been associated with cardiovascular disease (CVD), but it is not clear whether…”
Get full text

Findings from Left Ventricular Strain and Strain Rate Imaging in Asymptomatic Patients With Type 2 Diabetes Mellitus by Ng, Arnold C.T., MBBS, Delgado, Victoria, MD, Bertini, Matteo, MD, van der Meer, Rutger W., MD, Rijzewijk, Luuk J., MD, Shanks, Miriam, MD, Nucifora, Gaetano, MD, Smit, Johannes W.A., MD, PhD, Diamant, Michaela, MD, PhD, Romijn, Johannes A., MD, PhD, de Roos, Albert, MD, PhD, Leung, Dominic Y., MBBS, PhD, Lamb, Hildo J., MD, PhD, Bax, Jeroen J., MD, PhD

“…Regional left ventricular (LV) myocardial functional changes in early diabetic cardiomyopathy have not been well documented. LV multidirectional strain and…”
Get full text

Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans by van Raalte, Daniël H, van Genugten, Renate E, Linssen, Margot M.L, Ouwens, D. Margriet, Diamant, Michaela

“…OBJECTIVE: Glucocorticoids (GCs) are regarded as diabetogenic because they impair insulin sensitivity and islet-cell function. This study assessed whether…”
Get full text

Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease by Schindhelm, Roger K., Diamant, Michaela, Dekker, Jacqueline M., Tushuizen, Maarten E., Teerlink, Tom, Heine, Robert J.

“…For a long time, hepatic steatosis was believed to be a benign condition. Only recently, liver steatosis, also termed non‐alcoholic fatty liver disease…”
Get full text

Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies by Greulich, Sabrina, Chen, Weena J Y, Maxhera, Bujar, Rijzewijk, Luuk J, van der Meer, Rutger W, Jonker, Jacqueline T, Mueller, Heidi, de Wiza, Daniella Herzfeld, Floerke, Ralf-Ruediger, Smiris, Konstantinos, Lamb, Hildo J, de Roos, Albert, Bax, Jeroen J, Romijn, Johannes A, Smit, Jan W A, Akhyari, Payam, Lichtenberg, Artur, Eckel, Juergen, Diamant, Michaela, Ouwens, D Margriet

“…Adipokines are linked to the development of cardiovascular dysfunction in type 2 diabetes (DM2). In DM2-patients, circulating levels of omentin-1, an adipokine…”
Get full text

Endothelial Glycocalyx Damage Coincides With Microalbuminuria in Type 1 Diabetes by NIEUWDORP, Max, MOOIJ, Hans L, KASTELEIN, John J. P, STROES, Erik S. G, VINK, Hans, KROON, Jojanneke, ATASEVER, Bektas, SPAAN, Jos A. E, INCE, Can, HOLLEMAN, Frits, DIAMANT, Michaela, HEINE, Robert J, HOEKSTRA, Joost B. L

“…Endothelial Glycocalyx Damage Coincides With Microalbuminuria in Type 1 Diabetes Max Nieuwdorp 1 , Hans L. Mooij 1 , Jojanneke Kroon 1 , Bektas Atasever 2 ,…”
Get full text

Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men by van Raalte, Daniël H, Nofrate, Valentina, Bunck, Mathijs C, van Iersel, Thijs, Elassaiss Schaap, Jeroen, Nässander, Ulla K, Heine, Robert J, Mari, Andrea, Dokter, Wim H A, Diamant, Michaela

“…ObjectiveGlucocorticoids (GCs), such as prednisolone, are associated with adverse metabolic effects, including glucose intolerance and diabetes. In contrast to…”
Get full text